VTGN · Vistagen Therapeutics, Inc.
$0.27
-0.01 (-3.91%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, we had cash, cash equivalents, and marketable securities of approximately $31.7 million. As of August 14, 2026, the issuance date of the condensed consolidated financial statements in this Quarterly Report as of and for the three months ended June 30, 2026, there is uncertainty about whether our combined cash, cash equivalents, and marketable securities will be sufficient to fund operations beyond twelve months from the issuance date of the condensed consolidated financial statements in this Report and therefore we concluded that substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$12.11M
Shares
44.38M
Volume · Oct 5
1.64M
Avg daily vol (3M)
12.43M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.28
Open$0.28
Day$0.28–0.30
52W close$0.23–4.90
Avg vol 30d21.0M
Short int2.7M · 6.1% float · 7.6d
Short vol45%
Last earningsJun 30, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
call held Nov 13, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.50M
Trailing 12 months
Net income (TTM)
−$67.62M
Trailing 12 months
Revenue growth YoY
+504.9%
Year over year
Operating margin
-2,785.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+34.6%
Year over year · more shares
Price change (1Y)
-92.2%
Trailing year
Short interest
6.1%
Latest settlement · 7.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−45%
below
Price vs 50-day avg
+9%
above
RSI (14)
52
neutral
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+14%
trailing
6-month return
−52%
trailing
YTD return
−57%
this year
Relative strength
−64%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-7% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.10% of float · ▲ +27.3% MoM · 7.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
53 holders — mid 3-yr range
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
−120%
Y/Y
EPS growth
−10%
Y/Y
Free cash flow
$-66.6M
Balance sheet
$369.7K
net cash
Quant / Vol
risk profile
Volatility
142%
annualized · 1-yr
Max drawdown
−95%
past year
ATR
13.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−45%
Bearish
Price vs 50-day avg
+9%
Bullish
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-7% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.10% of float · ▲ +27.3% MoM · 7.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
53 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 1%
Range high $5
vs 200-day avg -45%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VTGN
this stock
Vistagen Therapeutics, Inc.
|
$12.11M | -57.4% | -120.5% | — | 6.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VTGN | +2.9% | +14.1% | -51.6% | -8.7% | -57.4% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +3.2% | +14.6% | -63.7% | -9.6% | -70.3% |